{"disease":{"id":"glioblastoma-multiforme-gbm","name":"glioblastoma multiforme gbm"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05271240","title":"Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":432,"lead_sponsor_name":"Northwell Health","has_results":false},{"nct_id":"NCT06630260","title":"5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":182,"lead_sponsor_name":"Institute of Cancer Research, United Kingdom","has_results":false},{"nct_id":"NCT02465268","title":"Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":175,"lead_sponsor_name":"University of Florida","has_results":true},{"nct_id":"NCT02717962","title":"Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":118,"lead_sponsor_name":"Kintara Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04587830","title":"ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Polaris Group","has_results":false},{"nct_id":"NCT06781372","title":"Patient's Derived Organoids for Drug Screening in Glioblastoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT03025893","title":"A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Amsterdam UMC, location VUmc","has_results":false},{"nct_id":"NCT06939400","title":"Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Zhejiang Provincial People's Hospital","has_results":false},{"nct_id":"NCT06521567","title":"A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":83,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT06926075","title":"Early Phase Study of KESONOTIDE™in Participants With Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Filamon LTD","has_results":false},{"nct_id":"NCT05879367","title":"Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"Orbus Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07391215","title":"5G-PEARL: Paxalisib in Malignant Brain Tumours","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":64,"lead_sponsor_name":"Institute of Cancer Research, United Kingdom","has_results":false},{"nct_id":"NCT06616727","title":"The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":50,"lead_sponsor_name":"Shanghai Simnova Biotechnology Co.,Ltd.","has_results":false},{"nct_id":"NCT07416188","title":"Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT07120620","title":"PriCoTTF Study: TTFields Before and During Radiotherapy for Newly Diagnosed Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Sied Kebir","has_results":false},{"nct_id":"NCT05954858","title":"Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Northwell Health","has_results":false},{"nct_id":"NCT03050736","title":"Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Kintara Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06595186","title":"JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"JenKem Technology Co., Ltd.","has_results":false},{"nct_id":"NCT04019002","title":"Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Susan Chang","has_results":false},{"nct_id":"NCT07497373","title":"A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Jecho Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT06632236","title":"5G-EMERALD: Amivantamab in Malignant Brain Tumours","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Institute of Cancer Research, United Kingdom","has_results":false},{"nct_id":"NCT03630289","title":"Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":12,"lead_sponsor_name":"Northwell Health","has_results":false},{"nct_id":"NCT03119064","title":"BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"Brown University","has_results":true},{"nct_id":"NCT02663271","title":"TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"University of Florida","has_results":true},{"nct_id":"NCT06806228","title":"Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":10,"lead_sponsor_name":"Petrov, Andrey","has_results":false},{"nct_id":"NCT04222309","title":"Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":10,"lead_sponsor_name":"Northwell Health","has_results":false},{"nct_id":"NCT00107003","title":"GW572016 to Treat Recurrent Malignant Brain Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04782609","title":"Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Samus Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03149575","title":"VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"DelMar Pharmaceuticals, Inc.","has_results":false}],"total":29},"guidelines":[],"source":"Drug Landscape verified database"}